Gambro Healthcare's management slammed by FDA
This article was originally published in Clinica
Executive Summary
In a strongly-worded warning letter, the FDA has criticised the president and top executives of Gambro Healthcare for poor management, the most recent of a total of six warning letters issued since 1992. Specifically referring to the management, the FDA mentions numerous cases of failure.